Industry Hopes FDA’s New Combo Products Chief Speeds Up Pending Rules
Executive Summary
FDA's Office of Combination Products says it is getting back on track with new leadership in place after months of flux. Industry meanwhile is pushing the office to accelerate the release of rules and guidelines to help companies navigate this relatively new area of regulation
You may also be interested in...
Drug/Device Combos With Cross-Labeling To Generics May Pose Liability Risks
Drug/device cross-labeling to generics poses added liability problems, stakeholders at a recent Regulatory Affairs Professional Society meeting said
Industry Involvement In Guidance Development Encouraged By FDA Working Group
In a report on best practices for guidance development, FDA encourages outside groups to submit their own draft guidance proposals to help make the overall process more efficient.
Industry Involvement In Guidance Development Encouraged By FDA Working Group
In a report on best practices for guidance development, FDA encourages outside groups to submit their own draft guidance proposals to help make the overall process more efficient.